Doctors are looking for ways to improve treatment for NSCLC. In this trial, they are looking at an experimental drug called BNT327. It is a new type of immunotherapy drug . It works in 2 ways. It aims ...

This trial is comparing BNT327 and standard chemotherapy with atezolizumab and standard chemotherapy. It is for people having their first treatment for small cell lung cancer that has spread within ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

BioNTech’s BNT327, a next-generation bispecific antibody candidate targeting PD-L1 and VEGF-A, is currently being evaluated in multiple ongoing trials with more than 1,000 patients treated to date, ...

BNT327/PM8002 is designed to restore effector T-cell function by binding to PD-L1, as well as localize VEGF-A neutralization within the tumor microenvironment, therefore reversing the dampening of ...

GERMAN drug developer BioNTech has signed an agreement with US pharmaceutical giant Bristol Myers Squibb (BMS) to manufacture a new cancer treatment, in a deal worth up to US$11bn. The new drug, ...

On Tuesday, TD Cowen maintained its Hold rating on BioNTech (NASDAQ: BNTX) with a steady price target of $122.00. The firm's analysis is based on the latest Phase 1b/2 data for BioNTech's BNT327 ...

Investing.com -- Shares in BioNTech (NASDAQ: BNTX) soared sharply Monday after Bristol-Myers Squibb Company (NYSE: BMY) agreed to pay $1.5 billion upfront to collaborate with the German biotech firm ...

BioNTech SE has signed a definitive agreement to acquire Biotheus, a clinical-stage biotech company, with the goal of enhancing its oncology strategy. The acquisition includes access to BNT327/PM8002, ...